Navigation Links
Cancer Drug Works Against MS in Early Trial
Date:2/13/2008

Promising results need to be replicated in larger study, experts caution

WEDNESDAY, Feb. 13 (HealthDay News) -- A drug originally designed to combat cancer that is now being used to treat autoimmune diseases such as rheumatoid arthritis and lupus might also work against a common form of multiple sclerosis.

In new research published in the Feb. 14 issue of the New England Journal of Medicine, researchers reported that one treatment with rituximab significantly reduced the number of inflammatory lesions in the brains of people with relapsing-remitting multiple sclerosis (MS), and almost halved the incidence of relapse for up to 48 weeks.

"The immediate results of this study should give great hope to all of us in the field and to our patients," said study author Dr. Stephen Hauser, chairman of the department of neurology at the University of California, San Francisco. "An easily-administered, relatively safe IV therapy might have a very important, profound effect on the relapsing-remitting phase of MS."

However, Hauser was quick to caution, "these results are preliminary and should not be translated into a belief that a new proven therapy has been identified." He said that larger, longer studies need to be done to fully assess the drug's safety and efficacy in people with MS.

"We are cautiously optimistic," Dr. John Richert, executive vice president of research and clinical programs for the National Multiple Sclerosis Society, said of the findings. "It's hard to imagine results any better than this, but right now, we don't have any long-term data on safety or efficacy."

MS is an autoimmune disease that affects the central nervous system. Instead of targeting foreign invaders, such as bacteria, the body mistakenly attacks the protective covering of nerve cells called myelin.

Most research has focused on the T-cell side of the immune system, but other studies began to suggest that maybe T-cells weren't the major players in MS after all, and that perhaps B-cells might play a role. Rituximab, sold under the brand name Rituxan, targets and depletes a type of B-cell known as CD20+.

Hauser's study included 104 people with relapsing-remitting multiple sclerosis. Someone with this type of MS will have disease flare-ups but will also have periods of remission when they don't have symptoms.

The volunteers were randomly assigned to receive either 1,000 milligrams of intravenous rituximab or a placebo. Magnetic resonance imaging (MRI) was conducted at 12, 16, 20 and 24 weeks to assess the number of inflammatory lesions -- a hallmark of MS -- present in the brain.

The number of lesions was reduced in people taking rituximab, and the number of people who had no new lesions was significantly less in those taking rituximab than in those taking a placebo, both during the study and six months later.

The rate of relapse was also significantly reduced for those on rituximab. At the end of the 48-week study period, 20.3 percent of those on rituximab had experienced a relapse versus 40 percent of those on placebo.

What both Hauser and Richert found most exciting was the speed at which rituximab worked and the duration of the benefit, which continued long after the treatment had been administered.

"Beneficial effects were seen by four weeks," said Richert. "Among the reasons why these data are so exciting is that the effects persist after 48 weeks after one course of rituximab."

People taking rituximab did experience more side effects, though most of them were minor. "The big question is whether removal of B-cells will impact the immune system later," said Hauser.

Both Hauser and Richert said this study has also provided new information about the MS disease process, and it will likely open up additional avenues of MS research.

More information

The National Multiple Sclerosis Society details the current treatments for the disease.



SOURCES: Stephen Hauser, M.D., Robert A. Fishman distinguished professor of neurology, and chairman, department of neurology, University of California, San Francisco; John Richert, M.D., executive vice president, research and clinical programs, National Multiple Sclerosis Society, New York City; Feb. 14, 2008, New England Journal of Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer Drug Works Against MS in Early Trial
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
Breaking Medicine Technology: